Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace

Holiday hiring hustle and bustle

Nov 15, 2019

Latest Episodes

Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy

Why Bill Ackman sees activist investing as a moral crusade

by Kai Ryssdal, Bridget Bodnar, and Sean McHenry Oct 31, 2017
For the Pershing Square Capital Management CEO, activist investing is just as much a moral calling as it is a lucrative one
Bill Ackman attends the Hamptons International Film Festival SummerDocs Series screening of 'Betting On Zero' at Guild Hall on August 6, 2016 in East Hampton, New York.
Matthew Eisman/Getty Images for Hamptons International Film Festival

Valeant Pharmaceuticals and the dark side of capitalism

by Kai Ryssdal Jun 10, 2016
Investors' demands for more profits left patients with the choice to pay up or die.
Howard Schiller, interim CEO of Valeant Pharmaceuticals International, and Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, listen during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC.
BRENDAN SMIALOWSKI/AFP/Getty Images

How to oust a corporate board member

by Tracey Samuelson Mar 24, 2016
Toppling Yahoo's entire board or removing one Valeant board member can be hard.
Yahoo CEO Marissa Mayer is facing pressure after a letter was sent to Yahoo's shareholders suggesting that the board and CEO should be replaced. 
Stephen Lam/Getty Images

Valeant's story: a cautionary tale

by Dan Gorenstein Mar 21, 2016
The company's CEO stepped down on Monday
Howard Schiller, then interim CEO of Valeant Pharmaceuticals International, Inc., listens during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC. 
BRENDAN SMIALOWSKI/AFP/Getty Images

Valeant swears off aggressive drug pricing strategy

by Dan Gorenstein Mar 15, 2016
Valeant and a handful other firms may ditch a model that's come under fire.
 Valeant and a handful other firms  may ditch a model that's come under fire.
Image via Life Science Association of Manitoba/YouTube

Valeant: how aggressively can a drug company sell

by Mitchell Hartman Oct 30, 2015
Valeant is under scrutiny for its business practices.

Why drugmakers are suddenly merging

by Dan Gorenstein Aug 20, 2015
Valeant Pharmaceuticals is purchasing Sprout for $1 billion.

Invest in Marketplace today

Ask not what Marketplace can do for you, but what you can do for Marketplace.